Volume 19, Number 1—January 2013
CME ACTIVITY - Research
Pneumocystis jirovecii Genotype Associated with Increased Death Rate of HIV-infected Patients with Pneumonia
Table 3
Risk factor |
Death attributed to PCP
|
Adjusted RH (95% CI)† | p value | |
---|---|---|---|---|
Yes | No | |||
P. jirovecii PCR-SSCP type | ||||
7 |
4 | 5 | 4.2 (1.0–17.9) | 0.05 |
Others |
14
|
89
|
1.0 (Reference)
|
|
Mechanical ventilation at PCP diagnosis | ||||
Yes |
8 | 6 | 5.0 (1.8–13.5) | 0.002 |
No |
10
|
88
|
1.0 (Reference)
|
|
DHPS genotype | ||||
M3 |
5 | 15 | 1.1 (0.4–3.4) | 0.82 |
M2 |
1 | 16 | 0.6 (0.08–5.1) | 0.66 |
Wild type |
12
|
63
|
1.0 (Reference)
|
|
Mean age at PCP diagnosis, y
|
38.5
|
40.6
|
1.0
|
0.95
|
First-line treatment | ||||
Others |
3 | 19 | 0.4 (0.1–2.0) | 0.29 |
Sulfonamides |
15 | 75 | 1.0 (Reference) |
*PCP, Pneumocystis jirovecii pneumonia; RH, relative hazard; SSCP, single-strand conformation polymorphism; DHPS, dihydropteroate synthase; M, mutation.
†RH for death attributed to PCP after adjustment for the 5 variables presented in the table. The global p value of the test for proportionality was 0.55, and no individual test was statistically significant at the 0.05 level.
Page created: December 20, 2012
Page updated: December 20, 2012
Page reviewed: December 20, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.